Aim: Clear cell carcinoma of the uterine cervix (CCCUC) is a rare disease, accounting for 4% to 9% of cervical adenocarcinomas. Because it is so rare, its pathogenesis is largely unknown, and the standard treatment is unclear due to a lack of prospective studies. Our aim is to investigate the clinical features, treatment, and prognosis of CCCUC.Methods: We retrospectively evaluated the clinical characteristics, treatment choices, and outcomes of 12 patients with CCCUC treated at our institution between January 2009 and July 2024.Results: The median patient age was 62.5 years (range, 14–90 years). The most common stage was IB (IA, n = 3; IB, n = 4; IIB, n = 1; IIIC, n = 2; IVB, n = 2). Ten patients underwent surgery as initial treatment: 6 underwent radical hysterectomy plus pelvic lymphadenectomy (PLD) or sentinel lymph node biopsy (SLNB), with or without para‐aortic lymphadenectomy (PALD); 3 underwent modified radical hysterectomy plus PLD with or without PALD; and 1 underwent radical trachelectomy with SLNB as fertility‐preserving surgery. All patients underwent bilateral salpingo‐oophorectomy except for the patient who opted for radical trachelectomy. Five patients received adjuvant treatment: 3 received platinum‐based systemic chemotherapy (2 of whom had combination therapy with bevacizumab), and 2 received concurrent chemoradiotherapy. The median follow‐up was 43.5 months (range, 1–123 months). The 5‐year progression‐free survival rate was 64.5%.Conclusion: Systemic platinum‐based chemotherapy with bevacizumab may be more effective than concurrent chemoradiotherapy as adjuvant therapy for CCCUC.

Background/Objectives: Under the current molecular classification of endometrial cancer, the p53-abnormal group is defined as having the worst prognosis, but the clinicopathological position of low-grade endometrial cancer with p53-abnormal expression relative to high-grade endometrial cancer remains unclear. We previously showed that low-grade endometrial cancer with p53-abnormal expression more closely resembles low-grade endometrial cancer with p53 wild-type expression than high-grade endometrial cancer and that the ERBB2 gene, encoding Human Epidermal Growth Factor Receptor 2 (HER2) protein, is more highly expressed in high-grade endometrial cancer. This study compared HER2 immunohistochemical expression (IHC) among low-grade endometrial cancer with wild-type p53 expression (EC^lop53^wt), low-grade endometrial cancer with p53-abnormal expression (EC^lop53^ab), and high-grade endometrial cancer (EC^hi), in order to characterize EC^lop53^ab. Methods: We retrospectively analyzed 70 endometrial cancer cases treated at Kyushu University Hospital in 1992–2022. Tumors were classified as EC^lop53^wt, EC^lop53^ab, and EC^hi based on histopathology and p53 immunohistochemistry, with EC^hi corresponding to conventional uterine serous carcinoma. HER2 expression was evaluated immunohistochemically using a standardized scoring system (0, 1+, 2+, 3+), and its distribution was compared across the three groups, together with clinicopathological parameters and patient outcomes. Results: EC^hi showed the highest frequency and intensity of HER2 expression, with a substantially larger proportion of HER2 IHC 3+ cases than EC^lop53^wt and EC^lop53^ab (p < 0.0001 and p = 0.0146, respectively). Meanwhile, there was no significant association between EC^lop53^wt and EC^lop53^ab (p = 0.3794). In addition, HER2 IHC 3+ had significant associations with older age (≥60 years) and substantial lymphovascular space invasion (p = 0.0003 and 0.0174, respectively). Conclusions: EC^lop53^ab exhibits HER2 profiles and clinical behavior more similar to EC^lop53^wt, supporting the more nuanced application of molecular classification and HER2-targeted therapy in endometrial cancer.